Matches in SemOpenAlex for { <https://semopenalex.org/work/W2410237089> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W2410237089 endingPage "302" @default.
- W2410237089 startingPage "296" @default.
- W2410237089 abstract "Treatment of metastatic renal cell carcinoma with interleukin 2 (IL2) remains controversial despite the authorization from the French government for IL2 with the West schedule in this disease. We report herein the study of the Institute Gustave-Roussy of 73 patients, who received from 1989 to 1991 a new schedule of high dose IL2. Seventy three patients received high dose IL2 according to the following schedule: IL2 by continuous infusion at 24.10(6) IU/m2/d, on 2 consecutive days per week, during 5 weeks. This treatment was associated in the first 33 patients with gamma interferon at a dose of 5.10(6) IU/m2/d subcutaneously the days of IL2 infusion, during the 5 weeks of therapy. Immunotherapy was further continued in responding patients, either as an association of IL2 and LANAK (lymphokine-activated natural killer) cells, or as IL2 alone. Finally, when possible, surgery was performed on residual masses. Twenty five percent of objective responses (PR + CR) have been observed. Moreover, 12.3% CR has been obtained after the overall therapy. The global mean survival is 15 months, with a mean survival of 8, 18 and 24+ months depending on the status of the disease (progressive, stable or responding) after initial treatment with IL2. Tolerance of this schedule was good with an actual received dose of 90% of the planned doses, and patients could leave the hospital within 2 hours after the end of IL2 in 87% of the cycles. No toxic death was observed. Among the parameters observed for correlation with the clinical response, only performance status and level of sTNF-alpha R were significantly associated with the response." @default.
- W2410237089 created "2016-06-24" @default.
- W2410237089 creator A5010816406 @default.
- W2410237089 creator A5015955183 @default.
- W2410237089 creator A5028436035 @default.
- W2410237089 creator A5032986953 @default.
- W2410237089 creator A5034765880 @default.
- W2410237089 creator A5040708765 @default.
- W2410237089 creator A5044169031 @default.
- W2410237089 creator A5047207671 @default.
- W2410237089 creator A5049672639 @default.
- W2410237089 creator A5090993023 @default.
- W2410237089 date "1995-04-01" @default.
- W2410237089 modified "2023-09-27" @default.
- W2410237089 title "[Treatment of metastatic kidney neoplasms with a new interleukin 2 protocol: The experience of the Gustave-Roussy Institute]." @default.
- W2410237089 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10846540" @default.
- W2410237089 hasPublicationYear "1995" @default.
- W2410237089 type Work @default.
- W2410237089 sameAs 2410237089 @default.
- W2410237089 citedByCount "1" @default.
- W2410237089 countsByYear W24102370892012 @default.
- W2410237089 crossrefType "journal-article" @default.
- W2410237089 hasAuthorship W2410237089A5010816406 @default.
- W2410237089 hasAuthorship W2410237089A5015955183 @default.
- W2410237089 hasAuthorship W2410237089A5028436035 @default.
- W2410237089 hasAuthorship W2410237089A5032986953 @default.
- W2410237089 hasAuthorship W2410237089A5034765880 @default.
- W2410237089 hasAuthorship W2410237089A5040708765 @default.
- W2410237089 hasAuthorship W2410237089A5044169031 @default.
- W2410237089 hasAuthorship W2410237089A5047207671 @default.
- W2410237089 hasAuthorship W2410237089A5049672639 @default.
- W2410237089 hasAuthorship W2410237089A5090993023 @default.
- W2410237089 hasConcept C121608353 @default.
- W2410237089 hasConcept C126322002 @default.
- W2410237089 hasConcept C126894567 @default.
- W2410237089 hasConcept C141071460 @default.
- W2410237089 hasConcept C2776694085 @default.
- W2410237089 hasConcept C2777371288 @default.
- W2410237089 hasConcept C2777472916 @default.
- W2410237089 hasConcept C2777701055 @default.
- W2410237089 hasConcept C2778690821 @default.
- W2410237089 hasConcept C2778822529 @default.
- W2410237089 hasConcept C71924100 @default.
- W2410237089 hasConcept C90924648 @default.
- W2410237089 hasConceptScore W2410237089C121608353 @default.
- W2410237089 hasConceptScore W2410237089C126322002 @default.
- W2410237089 hasConceptScore W2410237089C126894567 @default.
- W2410237089 hasConceptScore W2410237089C141071460 @default.
- W2410237089 hasConceptScore W2410237089C2776694085 @default.
- W2410237089 hasConceptScore W2410237089C2777371288 @default.
- W2410237089 hasConceptScore W2410237089C2777472916 @default.
- W2410237089 hasConceptScore W2410237089C2777701055 @default.
- W2410237089 hasConceptScore W2410237089C2778690821 @default.
- W2410237089 hasConceptScore W2410237089C2778822529 @default.
- W2410237089 hasConceptScore W2410237089C71924100 @default.
- W2410237089 hasConceptScore W2410237089C90924648 @default.
- W2410237089 hasIssue "4" @default.
- W2410237089 hasLocation W24102370891 @default.
- W2410237089 hasOpenAccess W2410237089 @default.
- W2410237089 hasPrimaryLocation W24102370891 @default.
- W2410237089 hasRelatedWork W169148751 @default.
- W2410237089 hasRelatedWork W2011188477 @default.
- W2410237089 hasRelatedWork W2151709130 @default.
- W2410237089 hasRelatedWork W2371937395 @default.
- W2410237089 hasRelatedWork W2395338486 @default.
- W2410237089 hasRelatedWork W2411817937 @default.
- W2410237089 hasRelatedWork W2414109243 @default.
- W2410237089 hasRelatedWork W2421099513 @default.
- W2410237089 hasRelatedWork W2428961132 @default.
- W2410237089 hasRelatedWork W2494898484 @default.
- W2410237089 hasVolume "82" @default.
- W2410237089 isParatext "false" @default.
- W2410237089 isRetracted "false" @default.
- W2410237089 magId "2410237089" @default.
- W2410237089 workType "article" @default.